off
FDA approves new generic version of schizophrenia treatment
Alkermes Plc. (ALKS) said the U.S. Food and Drug Administration has approved ARISTADA (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia. Aristada, poised to be launched immediately, will offer once-a-month and six-week dosing...
Posted On Oct 06 2015
